1stOncology™: Cancer Intelligence Service – Page 10763 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Centene Corporation’s 2020 Second Quarter Financial Results Conference Call

On July 6, 2020 Centene Corporation (NYSE: CNC) reported that it will release its 2020 second quarter financial results at approximately 6 a.m. (Eastern Time) on Tuesday, July 28, 2020, and host a conference call afterwards at approximately 8:30 a.m. (Eastern Time) to review the results. Michael F. Neidorff, Chairman, President and Chief Executive Officer, and Jeffrey A. Schwaneke, Executive Vice President and Chief Financial Officer, of Centene Corporation will host the call (Press release, Centene , JUL 6, 2020, View Source [SID1234561706]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Investors and other interested parties are invited to listen to the conference call by dialing 1-877-883-0383 in the U.S. and Canada; +1-412-902-6506 from abroad, including the following Elite Entry Number: 0580014, to expedite caller registration; or via a live, audio webcast on the Company’s website at www.centene.com, under the Investors section.

A webcast replay will be available for on-demand listening shortly after the completion of the call for the next 12 months or until 11:59 p.m. (Eastern Time) on Tuesday, July 27, 2021, at the aforementioned URL. In addition, a digital audio playback will be available until 9 a.m. (Eastern Time) on Tuesday, August 4, 2020, by dialing 1-877-344-7529 in the U.S. and Canada, or +1-412-317-0088 from abroad, and entering access code 10145373.

Haemonetics Sets Date for Publishing First Quarter Fiscal Year 2021 Results: August 4, 2020

On July 6, 2020 Haemonetics Corporation (NYSE:HAE) reported that the Company intends to publish first quarter fiscal year 2021 financial results at 6:00 am EDT on Tuesday, August 4, 2020 (Press release, Haemonetics, JUL 6, 2020, View Source [SID1234561705]). The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am EDT on August 4, 2020.

The call can be accessed with the following information:

A live webcast of the call can be accessed on Haemonetics’ investor relations website. Webcast Link: View Source

A webcast replay will be available August 4, 2020 after 11:00 am EDT.

McKesson Corporation to Announce First Quarter Fiscal 2021 Results on August 3, 2020

On July 6, 2020 McKesson Corporation (NYSE:MCK) reported that it will release its first quarter fiscal 2021 financial results before market open on Monday, August 3, 2020 (Press release, McKesson, JUL 6, 2020, View Source [SID1234561704]). The company will host a live webcast of the earnings conference call for investors at 8:00 AM Eastern Time to review its financial results.

The live webcast will be available on McKesson’s Investor Relations website at View Source, along with the company’s earnings press release, financial tables and slide presentation.

Pacira BioSciences Reports Preliminary Total Revenue of $75.5 Million for Second Quarter of 2020

On July 6, 2020 Pacira BioSciences, Inc. (Nasdaq: PCRX), a leading provider of innovative non-opioid pain management options, reported preliminary unaudited net revenue of $75.5 million for the second quarter of 2020, compared to $102.6 million for the second quarter of 2019 (Press release, Pacira Pharmaceuticals, JUL 6, 2020, View Source [SID1234561703]). During the second quarter of 2020, average daily sales of EXPAREL (bupivacaine liposome injectable suspension) were 30 percent, 81 percent and 107 percent of the prior year for the months of April, May, and June, respectively. During the second quarter of 2020, the Company’s product sales were negatively impacted by the COVID-19 pandemic, which mandated significant postponement or suspension in the scheduling of elective surgical procedures resulting from public health guidance and government directives. Elective surgery restrictions began to lift on a state-by-state basis in April 2020.

"We are very encouraged by the rapid recovery and consistent uptake in EXPAREL sales and ordering accounts on a weekly basis since the peak of the COVID-19 pandemic impact in April," said Dave Stack, chairman and chief executive officer of Pacira BioSciences. "Ambulatory surgical centers have quickly returned to the operating room to accommodate patients who were required to wait for important surgical interventions during COVID-19-related shutdowns. These customers have been key to our return to year-over-year growth and underscore our investment in working closely with our anesthesia partners to broaden the use of long-acting EXPAREL regional approaches as a cornerstone for multimodal opioid-sparing strategies that continue to enable the shift of inpatient procedures to the 23-hour stay environment."

Second Quarter Financial Highlights

•Net product sales of EXPAREL/bupivacaine liposome injectable suspension for the second quarter of 2020 were $73.8 million, compared to $99.8 million in the same period in 2019.
•EXPAREL net product sales for the second quarter of 2020 were $73.0 million, compared to $98.9 million in the same period in 2019. Sales of bupivacaine liposome injectable suspension to a third-party licensee for use in veterinary practice for the second quarter of 2020 were $0.8 million, compared to $0.9 million in the same period in 2019.
•iovera° net product sales for the second quarter of 2020 were $1.4 million, compared to $2.0 million in the same period in 2019. Pacira began recognizing sales of iovera° in April 2019 after completing its acquisition of MyoScience, Inc., a privately held medical technology company.
•Royalty revenue for the second quarter of 2020 was $0.3 million, compared to $0.8 million for the same period in 2019.

The financial information included in this press release is preliminary, unaudited and subject to adjustment. It does not present all information necessary for an understanding of the company’s second quarter financial results for 2020. Pacira expects to report its complete financial results for the second quarter and first half of 2020 during the Company’s conference call scheduled for August 2020.

LabCorp to Announce Second Quarter Financial Results on July 28, 2020

On July 6, 2020 LabCorp (NYSE: LH) reported that it will release its second quarter of 2020 financial results before the market opens on Tuesday, July 28, 2020, and then will host a conference call and webcast beginning at 9:00 a.m. EDT to discuss the results (Press release, LabCorp, JUL 6, 2020, View Source [SID1234561701]). The earnings release and accompanying financial information will be posted on the LabCorp Investor Relations website.

Interested parties can access the conference call by dialing 1-877-898-8036 within the U.S. and Canada, or 1-720-634-2811 internationally, using the passcode 2597361. In addition, a real-time webcast of the conference call will be available on the LabCorp Investor Relations website.

An audio replay of the conference call will be available from 1:00 p.m. EDT on July 28, 2020, until 11:30 a.m. EDT on August 11, 2020, by dialing 1-855-859-2056 within the U.S. and Canada, or 1-404-537-3406 internationally, using the passcode 2597361. The webcast of the conference call will be archived and accessible through July 14, 2021, on the LabCorp Investor Relations website.